Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib

Darapladib, a lipoprotein-associated phospholipase A2 (Lp-PLA(2)) inhibitor, failed to demonstrate efficacy for the primary endpoints in two large phase III cardiovascular outcomes trials, one in stable coronary heart disease patients (STABILITY) and one in acute coronary syndrome (SOLID-TIMI 52). N...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Yeo, Astrid, Li, Li, Warren, Liling, Aponte, Jennifer, Fraser, Dana, King, Karen, Johansson, Kelley, Barnes, Allison, MacPhee, Colin, Davies, Richard, Chissoe, Stephanie, Tarka, Elizabeth, O’Donoghue, Michelle L., White, Harvey D., Wallentin, Lars, Waterworth, Dawn
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5533343/
https://ncbi.nlm.nih.gov/pubmed/28753643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0182115
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
A carregar...

Registos relacionados